EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY-NC-ND 4.0

Efficacy and safety of sustained-release intracameral travoprost implant (iDose TR) for open-angle glaucoma and ocular hypertension: A systematic review

Bhavya Yarlagadda, Pranotti Pramodkumar Kakde, Susaritha Govindan

Journal of Clinical Ophthalmology and Research · 2026-10 · 14 (4) · 475-482

DOI: 10.4103/jcor.jcor_265_26 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Journal of Clinical Ophthalmology and Research, online erschienen am 18.11.2026. Verfasst von Bhavya Yarlagadda und 2 weiteren Autor:innen. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glaucoma is the leading cause of irreversible blindness, with intraocular pressure (IOP) reduction acting as the sole modifiable risk factor. While topical prostaglandin analogs (PGAs) serve as first-line therapies, they are frequently limited by poor adherence, preservative-related toxicity, and subtherapeutic dosing. This systematic review evaluated the efficacy, safety, and drug delivery performance of the Food and Drug Administration-approved travoprost intracameral implant (iDose TR), which provides continuous, preservative-free medication directly into the anterior chamber. Following Preferred Reporting Items for Systematic Reviews and MetaAnalyses 2020 guidelines, a comprehensive literature search was conducted across PubMed, Scopus, Cochrane Cochrane Central Register of Controlled Trial, and EMBASE through August 2025 to identify peer-reviewed clinical trials and real-world studies reporting on IOP, drug burden, or safety in open-angle glaucoma or ocular hypertension. Eight studies encompassing 1457 patients were analyzed. In Phase 3 trials, the slow-eluting implant demonstrated noninferiority to timolol 0.5% BID up to 3 months, achieving a mean IOP reduction of 6.0–7.5 mmHg. By 12 months, 81% of implant eyes remained medication-free, and the implant outperformed prestudy topical PGA monotherapy by an additional 1.31 mmHg reduction ($p = 0.0003$). Phase 2b data confirmed sustained 36-month effectiveness and stable corneal endothelial cell density (ECD), whereas real-world data showed a 33.2% mean IOP reduction at 3 months. Ultimately, the travoprost intracameral implant represents an effective sustained-release platform that overcomes adherence and bioavailability barriers. However, given that real-world data are currently limited to short-term (3-month) follow-up, conclusions regarding long-term safety, particularly ECD, must be interpreted with caution.

Zitieren

APA

Yarlagadda, B., Kakde, P. P., & Govindan, S. (2026). Efficacy and safety of sustained-release intracameral travoprost implant (iDose TR) for open-angle glaucoma and ocular hypertension: A systematic review. Journal of Clinical Ophthalmology and Research, 14(4), 475-482. https://doi.org/10.4103/jcor.jcor_265_26

Vancouver

Yarlagadda B, Kakde PP, Govindan S. Efficacy and safety of sustained-release intracameral travoprost implant (iDose TR) for open-angle glaucoma and ocular hypertension: A systematic review. Journal of Clinical Ophthalmology and Research. 2026;14(4):475-482. doi:10.4103/jcor.jcor_265_26

BibTeX
@article{Yarlagadda2026,
  author = {Yarlagadda, Bhavya and Kakde, Pranotti Pramodkumar and Govindan, Susaritha},
  title = {Efficacy and safety of sustained-release intracameral travoprost implant (iDose TR) for open-angle glaucoma and ocular hypertension: A systematic review},
  journal = {Journal of Clinical Ophthalmology and Research},
  year = {2026},
  volume = {14},
  number = {4},
  pages = {475--482},
  doi = {10.4103/jcor.jcor_265_26}
}
Kostenlos starten →